Home › Hairloss Labs › Female Pattern Hair Loss: Clinical Workup, Grading and Treatment Evidence

Hairloss Labs · Women's hair loss

Female Pattern Hair Loss: Clinical Workup, Grading and Treatment Evidence

How dermatologists assess FPHL: Ludwig, Sinclair and Savin grading, trichoscopy, which labs are ordered and when, and the trial data on spironolactone and low-dose oral minoxidil.

By Scott Blaine Hoffman · November 9, 2026 · 6 min read

Female pattern hair loss (FPHL) is the most common cause of chronic thinning in women, and it is usually diagnosed in the clinic rather than the lab. The workup is less about proving the diagnosis than about two other jobs: grading how far it has progressed, and finding anything that is making it worse, such as low iron, thyroid disease or excess androgens. This guide walks through that workup and then through the trial data for the treatments most often discussed.

Step 1: Recognise the pattern

FPHL typically causes gradual thinning over the crown and mid-scalp with the frontal hairline kept, so the central part looks wider over time. Three distributions are described (Herskovitz and Tosti, Int J Endocrinol Metab 2013):

Diffuse shedding that started a few months after an illness, childbirth or a new medicine points more toward telogen effluvium, which often unmasks or overlaps with FPHL. Separating the two is covered in our differential diagnosis guide.

Step 2: Grade the severity

ScaleStructureWhat it is good forLimitation
Ludwig3 grades, from mild crown thinning to extensive loss over the topQuick shorthand in notes and older studiesToo coarse to show change over a year of treatment
Sinclair5 points based on the width of the central partFiner steps; easy to repeat at follow-upDoes not capture frontal accentuation well
SavinA graded series of images of the central part, plus a separate frontal categoryCommon in clinical trials; shows density as well as part widthNeeds the reference images to hand

Whichever scale is used, the same scale should be used at every visit, alongside photographs of the part taken from the same angle and distance. In the Sinclair spironolactone study discussed below, mid-scalp grade at baseline was the only factor that predicted response, which is a practical reason to grade carefully at the start.

Step 3: Look closely at the scalp

Trichoscopy (scalp dermoscopy) helps confirm FPHL early and distinguish it from other causes. The key finding is variability in hair shaft diameter affecting at least 20% of hairs, together with more fine vellus hairs, both signs of follicle miniaturisation (Herskovitz and Tosti). Dermoscopy can also show features of diffuse alopecia areata, such as tapered fractured hairs, which change the plan entirely (StatPearls, NCBI Bookshelf). A scalp biopsy is usually unnecessary and is kept for cases where the diagnosis remains unclear.

Step 4: Order the right labs, and only those

Most women with FPHL have normal hormone levels and no signs of androgen excess. Testing is therefore split into a baseline set that looks for aggravating factors and an androgen set that is ordered when the history or examination suggests it.

TestWhyWhen it is usually ordered
Complete blood count and ferritin, with iron studiesIron deficiency is common and can increase sheddingMost women with thinning or shedding
Thyroid functionBoth under- and over-active thyroid cause diffuse lossMost women with thinning or shedding
25-hydroxyvitamin DLow levels are often corrected as part of general careCommonly included; evidence of a direct effect on FPHL is mixed
Testosterone with SHBG, DHEA, androstenedione and related markersTo detect androgen excessIrregular periods, acne, hirsutism, infertility or other signs of hyperandrogenism
Syphilis serologyA rare mimic of diffuse lossOnly when clinically suspected

The thyroid, ferritin and vitamin D baseline and the androgen panel above follow the review by Herskovitz and Tosti; StatPearls lists blood count, iron studies and thyroid tests as the core set. Irregular menses, a raised BMI or skin signs of androgen excess should prompt evaluation for polycystic ovary syndrome. How to read ferritin and vitamin D results is covered in our guide to vitamins and hair loss labs.

Step 5: Treatment, and what the trials show

Topical minoxidil

Topical minoxidil remains the approved first-line treatment for women. It needs about 12 months of consistent use before judging, and if it works it is continued, because stopping can trigger a shed (Herskovitz and Tosti). Practical questions about application and early shedding are in our minoxidil FAQ.

Low-dose oral minoxidil

Low-dose oral minoxidil is used off-label, particularly for women who cannot tolerate the topical. In a randomised trial of 52 women with FPHL, 1 mg oral minoxidil daily was compared with 5% topical minoxidil daily for 24 weeks. Hair density rose by 12% with oral and 7.2% with topical treatment; the difference was not statistically significant. Excess facial or body hair occurred in 27% on oral treatment versus 4% on topical, and resting heart rate rose about 10% without tachycardia (Ramos et al., J Am Acad Dermatol).

The largest safety dataset is a retrospective study of 1,404 patients across 10 centres, about 68% of them women. Hypertrichosis was the most frequent effect at 15.1%; lightheadedness (1.7%), fluid retention (1.3%) and tachycardia (0.9%) were uncommon, and 1.2% stopped because of systemic effects (Vañó-Galván et al., J Am Acad Dermatol 2021). Blood pressure, heart disease and pregnancy plans are reviewed before prescribing.

Spironolactone

Spironolactone is an androgen receptor blocker used off-label for FPHL, usually at 50 to 200 mg a day. In an open study of 80 women with biopsy-confirmed FPHL treated for at least 12 months with spironolactone 200 mg or cyproterone acetate, 44% had regrowth, 44% were stable and 12% progressed (Sinclair et al., Br J Dermatol 2005). There was no placebo group, and the authors themselves called for one, since stabilisation alone is hard to judge without knowing the natural course.

Common side effects include menstrual irregularity, dizziness, headache, rash and raised potassium; fewer than 5% of patients stop because of them (StatPearls). In healthy young women taking spironolactone for acne, hyperkalaemia occurred in 0.72% of tests, essentially the background rate (Plovanich et al., JAMA Dermatol 2015). Older women and those with kidney disease or on interacting drugs are a different group and are usually monitored. Spironolactone is not used in pregnancy, so contraception is discussed.

Finasteride and other antiandrogens

Finasteride at 1 mg showed no benefit in a controlled study of postmenopausal women. Small studies used 2.5 to 5 mg, and because it can affect a male fetus, it requires reliable contraception before menopause (Herskovitz and Tosti). Cyproterone acetate is used outside the United States but is not available there.

Treatment evidence at a glance

OptionBest evidenceMain trade-offs
Topical minoxidilApproved; multiple controlled trialsDaily use indefinitely; scalp irritation; initial shed
Oral minoxidil 1 mgOne 52-woman RCT vs topical; large safety seriesUnwanted hair growth; heart rate; off-label
Spironolactone 50 to 200 mgOpen 80-woman study; no placebo trialMenstrual changes; potassium; not in pregnancy
FinasterideNegative at 1 mg in postmenopausal women; small higher-dose studiesContraception essential before menopause

When thinning in a woman needs prompt assessment

  • Irregular or absent periods, new acne or coarse facial hair alongside thinning, which can signal androgen excess
  • Rapid virilising signs such as voice deepening or temple recession over months, which need urgent hormonal evaluation
  • Patches, a smooth shiny scalp, redness or scale around follicles, which suggest alopecia areata or a scarring alopecia rather than FPHL
  • Heavy periods with fatigue, which make iron deficiency more likely
  • Any plan to start oral minoxidil or spironolactone while pregnant, breastfeeding or trying to conceive

Talk it through before you decide

Ask Hairloss AI, powered by Regrowth Intelligence, about your own pattern and the questions to bring to a consultation. When you're ready, find a vetted hair restoration specialist near you.

Sources

By Scott Blaine Hoffman, founder of Regrowth.com, 30+ years in the hair-loss field. Published November 9, 2026 in Hairloss Labs.

Educational information, not medical advice. Talk to a doctor or dermatologist about your own hair loss before starting or stopping any treatment.

Hairloss Labs

More from Hairloss Labs

Evidence-based articles on hair loss, treatments and hair restoration, reviewed against medical sources.

See every article in Hairloss Labs →